We describe a novel series of imidazopyridine substituted phenylalanines which are potent VLA-4 antagonists. A wide variety of substituents are tolerated as replacements for the pendant 3-pyridyl ring. A clear structure-activity relationship was identified around the substitution of the 3-amino-cyclobut-2-enone portion of the molecule. (c) 2008 Elsevier Ltd. All rights reserved.
We describe a novel series of imidazopyridine substituted phenylalanines which are potent VLA-4 antagonists. A wide variety of substituents are tolerated as replacements for the pendant 3-pyridyl ring. A clear structure-activity relationship was identified around the substitution of the 3-amino-cyclobut-2-enone portion of the molecule. (c) 2008 Elsevier Ltd. All rights reserved.
[EN] BICYCLIC AND HETEROBICYCLIC DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR PHARMACEUTICAL USES<br/>[FR] DÉRIVÉS BICYCLIQUES ET HÉTÉROBICYCLIQUES, LEURS PROCÉDÉS DE FABRICATION ET LEURS UTILISATIONS PHARMACEUTIQUES
申请人:UCB PHARMA SA
公开号:WO2008064830A1
公开(公告)日:2008-06-05
[EN] The present invention concerns bicyclic and heterobicyclic derivatives of formula I, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals. [FR] La présente invention concerne des dérivés bicycliques et hétérobicycliques de formule I, leurs procédés de fabrication, des compositions pharmaceutiques les contenant et leur utilisation comme produits pharmaceutiques.
Imidazopyridines as VLA-4 integrin antagonists
作者:David J. Phillips、Richard J. Davenport、Thierry A. Demaude、Fiona P. Galleway、Mark W. Jones、Laurent Knerr、Benjamin G. Perry、Andrew J. Ratcliffe
DOI:10.1016/j.bmcl.2008.05.075
日期:2008.7
We describe a novel series of imidazopyridine substituted phenylalanines which are potent VLA-4 antagonists. A wide variety of substituents are tolerated as replacements for the pendant 3-pyridyl ring. A clear structure-activity relationship was identified around the substitution of the 3-amino-cyclobut-2-enone portion of the molecule. (c) 2008 Elsevier Ltd. All rights reserved.